Admission to Trading
Oxford Biomedica PLC has applied to the London Stock Exchange for the admission to trading of 5,654 ordinary shares of 50 pence each, which were allotted under the Company's Long Term Incentive Plan. Admission is expected to become effective on 09 October 2026, and these new ordinary shares will rank equally with existing shares.
Select text to share a quote on X · sign in to keep highlights & notes in your OXB notes
Oxford, UK – 06 October 2026: OXB (LSE: OXB), a quality and innovation-led cell and gene therapy CDMO, today announces that application has been made to the London Stock Exchange for the admission to trading of 5,654 ordinary shares of 50 pence each in the Company (the “New Ordinary Shares”).
The requested admission relates to ordinary shares which have been allotted under:
OXB Long Term Incentive Plan (LTIP)
It is expected that admission becomes effective on 09 October 2026. The New Ordinary Shares will rank pari passu in all respects with the Company's existing ordinary shares in issue.
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.